Advertisement
Screener

EMERGENT BIOSOLUTIONS INC. (EBS) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

EMERGENT BIOSOLUTIONS INC. Comprehensive Income

EMERGENT BIOSOLUTIONS INC. (EBS) reported Comprehensive Income of -$180.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06

  • EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$180.10M.
  • EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was $7.40M, a 88.97% decline year-over-year.
  • EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$54.60M.
  • EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $51.80M, a 54.16% decline year-over-year.
  • EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $50.30M.
  • EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$190.10M.
  • EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$769.30M.
  • EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$192.40M, a 184.13% decline from fiscal 2021.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed
2026-06-30-$180.10M
10-Q · filed 2026-08-06
-$172.70M
10-Q · filed 2026-08-06
-$227.30M
derived: sum of 3 quarters · filed 2026-08-06
-$175.50M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$7.40M
10-Q · filed 2026-05-01
-$47.20M
derived: sum of 2 quarters · filed 2026-05-01
$4.60M
derived: sum of 3 quarters · filed 2026-05-01
-$9.40M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$54.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
-$2.80M
derived: sum of 2 quarters · filed 2026-02-27
-$16.80M
derived: sum of 3 quarters · filed 2026-08-06
$50.30M
10-K · filed 2026-02-27
2025-09-30$51.80M
10-Q · filed 2025-10-30
$37.80M
derived: sum of 2 quarters · filed 2026-08-06
$104.90M
10-Q · filed 2025-10-30
$75.70M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$14.00M
10-Q · filed 2026-08-06
$53.10M
10-Q · filed 2026-08-06
$23.90M
derived: sum of 3 quarters · filed 2026-08-06
$136.90M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$67.10M
10-Q · filed 2026-05-01
$37.90M
derived: sum of 2 quarters · filed 2026-05-01
$150.90M
derived: sum of 3 quarters · filed 2026-05-01
-$132.20M
derived: sum of 4 quarters · filed 2026-05-01
2024-12-31-$29.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$83.80M
derived: sum of 2 quarters · filed 2026-02-27
-$199.30M
derived: sum of 3 quarters · filed 2026-02-27
-$190.10M
10-K · filed 2026-02-27
2024-09-30$113.00M
10-Q · filed 2025-10-30
-$170.10M
derived: sum of 2 quarters · filed 2025-10-30
-$160.90M
10-Q · filed 2025-10-30
-$213.50M
derived: sum of 4 quarters · filed 2026-02-27
2024-06-30-$283.10M
10-Q · filed 2025-08-07
-$273.90M
10-Q · filed 2025-08-07
-$326.50M
derived: sum of 3 quarters · filed 2026-02-27
-$590.90M
derived: sum of 4 quarters · filed 2026-02-27
2024-03-31$9.20M
10-Q · filed 2025-05-08
-$43.40M
derived: sum of 2 quarters · filed 2026-02-27
-$307.80M
derived: sum of 3 quarters · filed 2026-02-27
-$571.80M
derived: sum of 4 quarters · filed 2026-02-27
2023-12-31-$52.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
-$317.00M
derived: sum of 2 quarters · filed 2026-02-27
-$581.00M
derived: sum of 3 quarters · filed 2026-02-27
-$769.30M
10-K · filed 2026-02-27
2023-09-30-$264.40M
10-Q · filed 2024-11-07
-$528.40M
derived: sum of 2 quarters · filed 2024-11-07
-$716.70M
10-Q · filed 2024-11-07
-$775.40M
derived: sum of 4 quarters · filed 2025-03-04
2023-06-30-$264.00M
10-Q · filed 2024-08-07
-$263.90M
10-Q · filed 2023-08-09
-$452.30M
10-Q · filed 2024-08-07
-$449.00M
10-Q · filed 2023-08-09
-$511.00M
derived: sum of 3 quarters · filed 2025-03-04
-$597.20M
derived: sum of 4 quarters · filed 2025-03-04
2023-03-31-$188.30M
10-Q · filed 2024-05-02
-$185.10M
10-Q · filed 2023-05-10
-$247.00M
derived: sum of 2 quarters · filed 2025-03-04
-$333.20M
derived: sum of 3 quarters · filed 2025-03-04
-$386.40M
derived: sum of 4 quarters · filed 2025-03-04
2022-12-31-$58.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04
-$144.90M
derived: sum of 2 quarters · filed 2025-03-04
-$198.10M
derived: sum of 3 quarters · filed 2025-03-04
-$192.40M
10-K · filed 2025-03-04
-$204.60M
10-K · filed 2023-03-01
2022-09-30-$86.20M
10-Q · filed 2023-12-11
-$74.80M
10-Q · filed 2022-11-09
-$139.40M
derived: sum of 2 quarters · filed 2023-12-11
-$133.70M
10-Q · filed 2023-12-11
-$124.90M
10-Q · filed 2022-11-09
$48.60M
derived: sum of 4 quarters · filed 2024-03-08
2022-06-30-$53.20M
10-Q · filed 2023-08-09
-$50.10M
10-Q · filed 2023-08-09
$134.80M
derived: sum of 3 quarters · filed 2024-03-08
$101.40M
derived: sum of 4 quarters · filed 2024-03-08
2022-03-31$3.10M
10-Q · filed 2023-05-10
$188.00M
derived: sum of 2 quarters · filed 2024-03-08
$154.60M
derived: sum of 3 quarters · filed 2024-03-08
$161.20M
derived: sum of 4 quarters · filed 2024-03-08
2021-12-31$184.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08
$151.50M
derived: sum of 2 quarters · filed 2024-03-08
$158.10M
derived: sum of 3 quarters · filed 2024-03-08
$228.70M
10-K · filed 2024-03-08
$240.10M
10-K · filed 2022-02-25
2021-09-30-$33.40M
10-Q · filed 2022-11-09
-$26.80M
derived: sum of 2 quarters · filed 2022-11-09
$43.80M
10-Q · filed 2022-11-09
$225.60M
derived: sum of 4 quarters · filed 2023-12-11
2021-06-30$6.60M
10-Q · filed 2022-08-02
$77.20M
10-Q · filed 2022-08-02
$259.00M
derived: sum of 3 quarters · filed 2023-12-11
$299.30M
derived: sum of 4 quarters · filed 2023-12-11
2021-03-31$70.60M
10-Q · filed 2022-04-29
$252.40M
derived: sum of 2 quarters · filed 2023-12-11
$292.70M
derived: sum of 3 quarters · filed 2023-12-11
$384.40M
derived: sum of 4 quarters · filed 2023-12-11
2020-12-31$181.80M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11
$222.10M
derived: sum of 2 quarters · filed 2023-12-11
$313.80M
derived: sum of 3 quarters · filed 2023-12-11
$290.00M
10-K/A · filed 2023-12-11
$289.70M
10-K · filed 2021-02-19
2020-09-30$40.30M
10-Q · filed 2021-11-05
$132.00M
derived: sum of 2 quarters · filed 2021-11-05
$108.20M
10-Q · filed 2021-11-05
$154.30M
derived: sum of 4 quarters · filed 2022-02-25
2020-06-30$91.70M
10-Q · filed 2021-07-30
$67.90M
10-Q · filed 2021-07-30
$114.00M
derived: sum of 3 quarters · filed 2022-02-25
$153.10M
derived: sum of 4 quarters · filed 2022-02-25
2020-03-31-$23.80M
10-Q · filed 2021-04-30
$22.30M
derived: sum of 2 quarters · filed 2022-02-25
$61.40M
derived: sum of 3 quarters · filed 2022-02-25
$51.40M
derived: sum of 4 quarters · filed 2022-02-25
2019-12-31$46.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25
$85.20M
derived: sum of 2 quarters · filed 2022-02-25
$75.20M
derived: sum of 3 quarters · filed 2022-02-25
$50.10M
10-K · filed 2022-02-25
2019-09-30$39.10M
10-Q · filed 2020-11-06
$29.10M
derived: sum of 2 quarters · filed 2020-11-06
$4.00M
10-Q · filed 2020-11-06
-$200.00K
derived: sum of 4 quarters · filed 2021-02-19
2019-06-30-$10.00M
10-Q · filed 2020-07-31
-$35.10M
10-Q · filed 2020-07-31
-$39.30M
derived: sum of 3 quarters · filed 2021-02-19
-$18.60M
derived: sum of 4 quarters · filed 2021-02-19
2019-03-31-$25.00M
10-Q · filed 2020-05-01
-$29.30M
derived: sum of 2 quarters · filed 2021-02-19
-$8.60M
derived: sum of 3 quarters · filed 2021-02-19
$40.30M
derived: sum of 4 quarters · filed 2021-02-19
2018-12-31-$4.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19
$16.40M
derived: sum of 2 quarters · filed 2021-02-19
$65.30M
derived: sum of 3 quarters · filed 2021-02-19
$60.90M
10-K · filed 2021-02-19
2018-09-30$20.70M
10-Q · filed 2019-11-07
$69.60M
derived: sum of 2 quarters · filed 2019-11-07
$65.20M
10-Q · filed 2019-11-07
2018-06-30$48.90M
10-Q · filed 2019-08-02
$44.50M
10-Q · filed 2019-08-02
2017-12-31$83.20M
10-K · filed 2020-02-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
ENANTA PHARMACEUTICALS INC (ENTA)United States$0.349B-6.72
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Rezolute, Inc. (RZLT)United States$0.382B-6.45